Medical device CRO Factory brings Boston Biomedical into its fold

Handshake business deal executives
Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO based in the Netherlands, has merged with U.S.-based Boston Biomedical Associates. (Pixabay)

Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO based in the Netherlands, has merged with U.S.-based Boston Biomedical Associates.

Financial terms of the deal weren’t announced.

With the addition of Boston Biomedical, Factory-CRO Group now boasts expanded operations in the U.S., as well as sites in Australia, New Zealand and Europe. Factory-CRO Group said its goal is to become the leading global CRO focused on medical devices and medical technology. 

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience,” Dirk Meijer, M.D., Ph.D., the company’s chief executive, said in a statement. “We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.”

A little over a year ago, Factory-CRO Group acquired Milestone Research Organization. Factory-CRO Group offers medical device companies services in data management, consultancy regarding study design and budget and regulatory strategy, regulatory filings, clinical monitoring and reimbursement.

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.